GC
NRIX icon

Globeflex Capital’s Nurix Therapeutics NRIX Stock Holding History

Globeflex Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-95,899
Closed -$990K – 501
2023
Q4 		$990K Sell
95,899
-44,601
-32% -$306K 0.1% 186
2023
Q3 		$1.1M Sell
140,500
-2,677
-2% -$24.4K 0.13% 162
2023
Q2 		$1.43M Buy
+143,177
New +$1.46M 0.16% 143

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Globeflex Capital's NRIX Position: Q1 2024 in Review

Globeflex Capital sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 95,899 shares — an estimated $990K sold.

Globeflex Capital first reported a position in NRIX in Q2 2023 and held it in 3 quarters. The position peaked at $1.43M in Q2 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

  • Globeflex Capital reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Globeflex Capital sold 95,899 Nurix Therapeutics shares in Q1 2024, an estimated $990K.
  • Globeflex Capital first reported a position in Nurix Therapeutics in Q2 2023 and held it in 3 quarters.
  • Globeflex Capital's Nurix Therapeutics position peaked at $1.43M in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on Globeflex Capital's 13F filing for Q1 2024, filed 14 May 2024.